Compare American Express Co (AXP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs BIO-TECHNE Corp — how do they compare? American Express Co trades at $341.58 (market cap $228.84B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: American Express Co is far larger — about 20.4× BIO-TECHNE Corp's market cap, and American Express Co pays the higher dividend (1.12%). Which is the better fit depends on your goals.
| AXP | TECH | |
|---|---|---|
Market Cap | $228.84B | $11.24B |
Sector | Financials | Health |
52-Week High | $384.82 | $72.29 |
52-Week Low | $292.27 | $43.31 |
Dividend Yield | 1.12% | 0.44% |
Enterprise Value | — | $11.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Express (AXP) trades at $340.91, down 0.49% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.53 EPS, beating estimates, and maintains robust fundamentals with 15.07% net income margin and 33.97% ROE. Recent news highlights Amex's focus on premium card member experiences and strategic investments in AI for small businesses.
AXP presents a compelling growth story with consistent revenue expansion and strong profitability, though premium valuation metrics (P/E 20.69, P/B 6.72) warrant caution. Analyst consensus leans bullish with a $369.42 price target, representing 8.4% upside potential. Key risks include competitive pressures in payments and sensitivity to economic cycles affecting consumer spending.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
